The goal of this clinical trial is to learn about effectiveness and safety of washing microbiota transplantation in diabetic gastrointestinal motility disorders participant population. The main questions it aims to answer are: * The risk factors of diabetic gastrointestinal motility disorders in routine clinical data or biochemical tests. * The composition of gut microbiota in diabetic gastrointestinal motility disorders patients and potential pathogenic bacteria. * The efficacy of washing microbiota transplantation in the clinical treatment of diabetic gastrointestinal motility disorders patients and potential factors that may influence treatment outcomes. * The potential mechanisms of washing microbiota transplantation in treating diabetic gastrointestinal motility disorders patients. Participants will be collected fasting venous blood and random stool samples before treatment and at week 12 post-treatment, conducting scale assessments before treatment and at weeks 1, 4, and 12 post-treatment.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
40
Fecal samples from healthy adults were collected and underwent multiple centrifugations and filtrations to obtain a bacterial solution, which was then transplanted into the duodenum of patients via a nasogastric tube.
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Gastrointestinal Symptom Rating Scale
Questionnaires，the minimum score is 0，and maximum is 45, and higher scores mean a worse outcome.
Time frame: 0 days，weeks 1, 4, and 12 post-treatment
Gut Microbiome Sequencing
16S rRNA Sequencing
Time frame: 0 days，weeks 12 post-treatment
Gastroparesis Cardinal Symptom Index
Questionnaires，the minimum score is 0，and maximum is 45, and higher scores mean a worse outcome.
Time frame: 0 days，weeks 1, 4, and 12 post-treatment
Composite Autonomic Symptom Score 31
Questionnaires，the minimum score is 0，and maximum is 75, and higher scores mean a worse outcome.
Time frame: 0 days，weeks 1, 4, and 12 post-treatment
Gastrointestinal Motility
Neurophysiological Method
Time frame: 0 days，weeks 12 post-treatment
Heart Rate Variability
Neurophysiological Method
Time frame: 0 days，weeks 12 post-treatment
Serum Metabolites
Liquid chromatography-mass spectrometry (LC-MS)
Time frame: 0 days，weeks 12 post-treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.